Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

A-020

Supelco

Amobarbital solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C11H18N2O3
Numero CAS:
57-43-2
Peso molecolare:
226.27
Numero MDL:
MFCD00057558
Codice UNSPSC:
41116107
ID PubChem:
329770580
NACRES:
NA.24

Grado

certified reference material

Forma fisica

liquid

Caratteristiche

SNAP-N-SPIKE®. SNAP-N-SHOOT®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

Concentrazione

1.0 mg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

forensics and toxicology

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

O=C(NC(C1(CC)CCC(C)C)=O)NC1=O

InChI

1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
VIROVYVQCGLCII-UHFFFAOYSA-N

Categorie correlate

Descrizione generale

A Certified Spiking Solution® for amobarbital testing methods by GC/MS or LC/MS for clinical toxicology, medication monitoring, forensic analysis, pain prescription monitoring, or urine drug testing applications. Amobarbital is a barbiturate approved for treatment of anxiety, insomnia, and epilepsy.

Applicazioni



  • Barbiturate biochemical analysis: A study detailed a new approach for the analysis of barbiturates, including amobarbital, using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), highlighting advancements in detecting and quantifying these substances in forensic and toxicological contexts (Wachełko et al., 2023).

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes,Central nervous system

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Pentobarbital-D5 solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

P-013

Pentobarbital-D5 solution

Triazolam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

T-910

Triazolam solution

Lorazepam solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-901

Lorazepam solution

Nitrazepam solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

N-906

Nitrazepam solution

Codeine solution 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-006

Codeine solution

Myxothiazol from Myxococcus fulvus Mx f85, ≥98% (HPLC)

Sigma-Aldrich

T5580

Myxothiazol

M Zijlmans et al.
Journal of neurology, 259(8), 1632-1638 (2012-01-27)
The purpose of this study was to evaluate the contribution of posterior circulation to memory function by comparing memory scores between patients with and without a foetal-type posterior cerebral artery (FTP) during the intracarotid amobarbital procedure (IAP) in epilepsy patients.
Qun Chen et al.
Journal of cardiovascular pharmacology, 59(1), 101-108 (2011-10-04)
Cardiac ischemia damages the mitochondrial electron transport chain and the damage persists during reperfusion. Ischemic postconditioning (PC), applied during early reperfusion, decreases cardiac injury. This finding suggests that the ischemia-damaged mitochondria can be regulated to decrease cardiac injury. The reversible
Julián Carvajal-Castrillón et al.
Revista de neurologia, 55(9), 520-527 (2012-11-01)
An appropriate localization of ictal onset zone in refractory temporal lobe epilepsy favors an adequate outcome associated with surgical treatment. When video-electroencephalogram (video-EEG) and magnetic resonance imaging do not provide accurate data to locate ictal onset zone, the use of
Kathrin Wagner et al.
Journal of neurology, neurosurgery, and psychiatry, 83(5), 503-509 (2012-03-08)
The Wada test has been the gold standard for testing cerebral language localisation during presurgical investigation in the past decades. However, during the last few years a shift has occurred in epilepsy surgery programmes towards the use of non-invasive methods
Jason Chui et al.
Anesthesia and analgesia, 116(4), 881-888 (2013-02-23)
Patients with medically refractory epilepsy when referred for surgical treatment often undergo extensive investigations to determine whether surgical treatment is feasible. Surgical feasibility is determined by identifying the location and number of seizure foci and their relationship to eloquent areas
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.